Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]

Abstract

Ren S, Song L, Tian Y, et al. Int J Nanomedicine. 2021;16:7463–7478. Page 7466, Cell Viability Assay and Apoptosis Analyses section, 3rd sentence, the text “Next, different concentrations of Fe3O4-PEG and Fe3O4-PEG-Cy7-EMO (0, 12.5, 25, 50, 80, 100 μg/mL) were added to the plates and incubated for 24 hours” should read “Next, different concentrations of Fe3O4-PEG and Fe3O4-PEG-Cy7-EMO (0, 6, 12, 25, 50, 80, 100 μg/mL) were added to the plates and incubated for 48 hours”. Page 7473, Table 1, the value “62.23%” in the BxPC-3 row for the Fe3O4-PEG-Cy7-EMO (80µg/mL) column should read “62.63%”. Page 7474, Figure 7A, due to an error at the time of figure assembly, the images for spleen and lung in the second and the third rows are identical. The correct Figure 7 is shown in Download Article. The authors apologize for these errors and advise they do not affect the results of the paper. Read the original article

Keywords

• pancreatic cancer
• emodin
• magnetic nanoparticles
• passive targeting